BioCentury | Jan 23, 2012
Clinical News

Isoniazide: Phase IIa started

...evaluate thrice-daily oral isoniazide for 12 weeks in about 60 patients with diabetic foot ulcers. Bridge Bioresearch plc...
BioCentury | Sep 28, 2009
Company News

Bridge Bioresearch, GENova, Suncheon Cheongam College deal

...GENova said it terminated a deal earlier this month with Bridge Bioresearch to share research on their...
...cells. GENova is developing tetanolic acid to treat breast cancer. Further terms were not disclosed. Bridge Bioresearch plc...
BioCentury | Sep 21, 2009
Company News

GENova, Bridge Bioresearch, Prime BioResearch deal

...with other compounds to treat prostate cancer. Also, in two separate deals, GENova partnered with Bridge Bioresearch...
...and cardiovascular disorders. Further terms were not disclosed. GENova Biotherapeutics Inc. (OTCBB:GVBP), New York, N.Y. Bridge Bioresearch plc...
Items per page:
1 - 3 of 3
BioCentury | Jan 23, 2012
Clinical News

Isoniazide: Phase IIa started

...evaluate thrice-daily oral isoniazide for 12 weeks in about 60 patients with diabetic foot ulcers. Bridge Bioresearch plc...
BioCentury | Sep 28, 2009
Company News

Bridge Bioresearch, GENova, Suncheon Cheongam College deal

...GENova said it terminated a deal earlier this month with Bridge Bioresearch to share research on their...
...cells. GENova is developing tetanolic acid to treat breast cancer. Further terms were not disclosed. Bridge Bioresearch plc...
BioCentury | Sep 21, 2009
Company News

GENova, Bridge Bioresearch, Prime BioResearch deal

...with other compounds to treat prostate cancer. Also, in two separate deals, GENova partnered with Bridge Bioresearch...
...and cardiovascular disorders. Further terms were not disclosed. GENova Biotherapeutics Inc. (OTCBB:GVBP), New York, N.Y. Bridge Bioresearch plc...
Items per page:
1 - 3 of 3